公开(公告)号：US5609930A

公开(公告)日：1997-03-11

申请号：US418376

申请日：1995-04-07

申请人： Takashi Matsunaga ,  Toshihiro Nishimura ,  Hiroshi Inoue

发明人： Takashi Matsunaga ,  Toshihiro Nishimura ,  Hiroshi Inoue

IPC分类号： B32B27/20 ,  B32B27/32 ,  B65D33/02

CPC分类号： B32B27/32 ,  Y10T428/1334 ,  Y10T428/1352 ,  Y10T428/24372 ,  Y10T428/24942 ,  Y10T428/2495 ,  Y10T428/24975 ,  Y10T428/258 ,  Y10T428/259 ,  Y10T428/31913

摘要： A bag for packaging heavy materials, exhibiting excellent strength, content packaging performance, stacking performance on the pallets, and anti-collapsing performance. The bag is made of a multi-layer laminated film which comprises an outermost layer of a polyethylene film containing an inorganic filler in an amount of from 20 to 80% by weight and an innermost layer of a polyethylene film containing an inorganic filler in an amount of from 10 to 40% by weight, the outermost layer having on the surface thereof a coefficient of static friction of not smaller than 0.5 (ASTM D 1894), a coefficient of dynamic friction of not larger than 0.5 (ASTM D 1894) and a gloss of not larger than 50% (JIS Z 8741, at a measuring angle of 60.degree.), and the content of the inorganic filler in the innermost layer being from 1/2 to 1/6 of the content of the inorganic filler in the outermost layer.

摘要翻译： 用于包装重材料的袋子，具有优异的强度，包装性能，托盘上的堆叠性能以及抗折叠性能。 该袋由多层层压膜制成，该多层层压膜包括含有20至80重量％的无机填料的聚乙烯膜的最外层，并且含有一定量的无机填料的聚乙烯膜的最内层 为10〜40重量％，最外层的表面的静摩擦系数为0.5以上（ASTM D 1894），动摩擦系数为0.5以下（ASTM D 1894）和 光泽度不大于50％（JIS Z 8741，测量角度为60度），最内层的无机填料的含量为+ E，fra 1/2 + EE至+ E， 6 + EE的最外层无机填料的含量。

公开(公告)号：US07465713B2

公开(公告)日：2008-12-16

申请号：US11247216

申请日：2005-10-12

申请人： Hideki Fujikura ,  Nobuhiko Fushimi ,  Toshihiro Nishimura ,  Takeshi Nakabayashi ,  Masayuki Isaji

发明人： Hideki Fujikura ,  Nobuhiko Fushimi ,  Toshihiro Nishimura ,  Takeshi Nakabayashi ,  Masayuki Isaji

IPC分类号： A01N43/04 ,  A61K31/70

CPC分类号： A61K45/06 ,  A61K31/7056 ,  C07H17/02 ,  A61K2300/00

摘要： The present invention provides glucopyranosyloxypyrazole derivatives represented by the general formula: wherein R represents a hydrogen atom, a lower alkyl group or a group forming a prodrug; one of Q and T represents a group represented by the general formula: (wherein P represents a hydrogen atom or a group forming a prodrug), while the other represents a lower alkyl group or a halo(lower alkyl) group; R2 represents a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a halo(lower alkyl) group or a halogen atom; and with the proviso that P does not represent a hydrogen atom when R represents a hydrogen atom or a lower alkyl group, or pharmaceutically acceptable salts thereof, which exert an inhibitory activity in human SGLT2 and have an improved oral absorption, and therefore are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications or obesity, and pharmaceutically acceptable salts thereof, and pharmaceutical uses thereof.

摘要翻译： 本发明提供由以下通式表示的吡喃葡萄糖氧吡唑衍生物：其中R表示氢原子，低级烷基或形成前药的基团; Q和T之一表示由通式表示的基团：（其中P表示氢原子或形成前药的基团），而另一个表示低级烷基或卤代（低级烷基）基团; R2表示氢原子，低级烷基，低级烷氧基，低级烷硫基，卤代（低级烷基）或卤素原子; 并且条件是当R表示氢原子或低级烷基时，P不表示氢原子，或其药学上可接受的盐，其在人SGLT2中具有抑制活性并具有改善的口服吸收，因此可用作 用于预防或治疗与高血糖相关的疾病如糖尿病，糖尿病并发症或肥胖症的药剂及其药学上可接受的盐及其药学用途。

公开(公告)号：US07172718B2

公开(公告)日：2007-02-06

申请号：US10747636

申请日：2003-12-29

申请人： Takayuki Tagawa ,  Tomohiro Miwa ,  Toshihiro Nishimura

发明人： Takayuki Tagawa ,  Tomohiro Miwa ,  Toshihiro Nishimura

IPC分类号： B29C47/06 ,  B29D29/08

CPC分类号： B29C47/0004 ,  B29C47/0023 ,  B29C47/065 ,  B29C47/261 ,  B29D29/00 ,  B29K2021/00 ,  B29K2105/06 ,  B29K2301/10 ,  B29L2031/7094

摘要： A method of manufacturing a power transmission belt having a body with a length and a cushion rubber layer in which at least one carrying member is embedded so as to extend lengthwise of the body. The method includes the steps of: extrusion molding (a) a first rubber composition including rubber with short fibers therein and (b) a second rubber composition that is different than the first rubber composition to produce a first sheet in which the second rubber composition defines at least a part of the cushion rubber layer; applying the at least one load carrying member to the second rubber composition to produce a preform assembly; and processing the preform assembly to produce a power transmission belt.

摘要翻译： 一种制造具有长度的本体和缓冲橡胶层的动力传递带的方法，其中至少一个承载构件被嵌入以沿身体的纵向延伸。 该方法包括以下步骤：挤压成型（a）包含短纤维的橡胶的第一橡胶组合物和（b）不同于第一橡胶组合物的第二橡胶组合物，以制备其中第二橡胶组合物定义的第一片 缓冲橡胶层的至少一部分; 将所述至少一个承载构件施加到所述第二橡胶组合物以产生预成型件组件; 并处理预制组件以产生动力传动带。

公开(公告)号：US07087579B2

公开(公告)日：2006-08-08

申请号：US10468454

申请日：2002-02-26

申请人： Toshihiro Nishimura ,  Nobuhiko Fushimi ,  Hideki Fujikura ,  Kenji Katsuno ,  Yoshimitsu Komatsu ,  Masayuki Isaji

发明人： Toshihiro Nishimura ,  Nobuhiko Fushimi ,  Hideki Fujikura ,  Kenji Katsuno ,  Yoshimitsu Komatsu ,  Masayuki Isaji

IPC分类号： A01N43/04 ,  A61K31/70 ,  C07H17/00

CPC分类号： C07H15/203 ,  C07H17/02

摘要： The present invention provides glucopyranosyloxypyrazole derivatives represented by the general formula: wherein one of Q and T represents a group represented by the general formula: while the other represents a lower alkyl group or a halo(lower alkyl) group; R1 represents a hydrogen atom, an optionally substituted lower alkyl group, a lower alkenyl group, a cyclic lower alkyl group, etc.; R2 represents a hydrogen atom, an optionally substituted lower alkyl group, a lower alkoxy group, a lower alkenyl group, a cyclic lower alkyl group, a cyclic lower alkoxy group, etc., which exert an excellent inhibitory activity in human SGLT2, and therefore are useful as drugs for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications or obesity, pharmaceutically acceptable salts thereof or prodrugs thereof, production intermediates thereof and pharmaceutical uses thereof.

公开(公告)号：US20060142209A1

公开(公告)日：2006-06-29

申请号：US11358400

申请日：2006-02-22

申请人： Toshihiro Nishimura ,  Nobuhiko Fushimi ,  Hideki Fujikura ,  Kenji Katsuno ,  Yoshimitsu Komatsu ,  Masayuki Isaji

发明人： Toshihiro Nishimura ,  Nobuhiko Fushimi ,  Hideki Fujikura ,  Kenji Katsuno ,  Yoshimitsu Komatsu ,  Masayuki Isaji

IPC分类号： A61K31/7052

CPC分类号： C07H15/203 ,  C07H17/02

摘要： The present invention provides glucopyranosyloxypyrazole derivatives represented by the general formula: wherein one of Q and T represents a group represented by the general formula: while the other represents a lower alkyl group or a halo(lower alkyl) group; R1 represents a hydrogen atom, an optionally substituted lower alkyl group, a lower alkenyl group, a cyclic lower alkyl group, etc.; R2 represents a hydrogen atom, an optionally substituted lower alkyl group, a lower alkoxy group, a lower alkenyl group, a cyclic lower alkyl group, a cyclic lower alkoxy group, etc., which exert an excellent inhibitory activity in human SGLT2, and therefore are useful as drugs for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications or obesity, pharmaceutically acceptable salts thereof or prodrugs thereof, production intermediates thereof and pharmaceutical uses thereof.

摘要翻译： 本发明提供由以下通式表示的吡喃葡萄糖氧吡唑衍生物：其中Q和T之一表示由通式表示的基团，而另一个代表低级烷基或卤代（低级烷基）基团; R 1表示氢原子，任选取代的低级烷基，低级烯基，环状低级烷基等; R 2表示氢原子，任选取代的低级烷基，低级烷氧基，低级烯基，环状低级烷基，环状低级烷氧基等，其具有优异的 因此可用作预防或治疗与糖尿病，糖尿病并发症或肥胖症，糖尿病并发症或肥胖症，糖尿病并发症或肥胖症，其药学上可接受的盐或其前药，与其生产中间体及其药物用途有关的疾病的药物。

公开(公告)号：US07045665B2

公开(公告)日：2006-05-16

申请号：US10959505

申请日：2004-10-07

申请人： Hideki Fujikura ,  Nobuhiko Fushimi ,  Toshihiro Nishimura ,  Kazuya Tatani ,  Kenji Katsuno ,  Masahiro Hiratochi ,  Yoshiki Tokutake ,  Masayuki Isaji

发明人： Hideki Fujikura ,  Nobuhiko Fushimi ,  Toshihiro Nishimura ,  Kazuya Tatani ,  Kenji Katsuno ,  Masahiro Hiratochi ,  Yoshiki Tokutake ,  Masayuki Isaji

IPC分类号： C07C39/12 ,  C07C27/10 ,  C07C33/18

CPC分类号： C07H15/203

摘要： The present invention relates to benzylphenol derivatives represented by the general formula: wherein R11 represents a hydrogen atom or a protected hydroxy(lower alkyl) group; and R12 represents a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a protected hydroxy(lower alkyl) group, a protected hydroxy(lower alkoxy) group, a protected hydroxy(lower alkylthio) group, a lower alkoxy-substituted (lower alkyl) group, a lower alkoxy-substituted (lower alkoxy) group or a lower alkoxy-substituted (lower alkylthio) group; with the proviso that R12 is not a methyl group, an ethyl group, an isopropyl group, a tert-butyl group or a methoxy group when R11 is a hydrogen atom, or a salt thereof, which are used as intermediates for making glucopyranosyloxybenzylbenzene compounds having inhibitory activity in human SGLT2 and are useful in treating diseases associated with hyperglycemia, such as diabetes.

摘要翻译： 本发明涉及由以下通式表示的苄基酚衍生物：其中R 11表示氢原子或被保护的羟基（低级烷基）基团; R 12表示低级烷基，低级烷氧基，低级烷硫基，被保护的羟基（低级烷基），被保护的羟基（低级烷氧基），被保护的羟基（低级烷硫基 ）基团，低级烷氧基取代的（低级烷基）基团，低级烷氧基取代的（低级烷氧基基团）或低级烷氧基取代的（低级烷硫基）基团; 条件是当R 11是氢原子时，R 12不是甲基，乙基，异丙基，叔丁基或甲氧基 或其盐，其用作制备在人SGLT2中具有抑制活性的吡喃葡萄糖氧基苄基苯化合物的中间体，并且可用于治疗与高血糖相关的疾病如糖尿病。

公开(公告)号：US20060035840A1

公开(公告)日：2006-02-16

申请号：US10540519

申请日：2003-12-19

申请人： Hideki Fujikura ,  Toshihiro Nishimura ,  Kenji Katsuno ,  Masayuki Isaji

发明人： Hideki Fujikura ,  Toshihiro Nishimura ,  Kenji Katsuno ,  Masayuki Isaji

IPC分类号： A61K31/7052 ,  C07H17/02

CPC分类号： C07H17/02 ,  A61K31/706

摘要： The present invention provides nitrogen-containing heterocyclic derivatives represented by the general formula: wherein X1 represents Nor CR1; X2 represents Nor CR2; X3 represents N or CR3; X4 represents N or CR4; and with the proviso that one or two of X1 to X4 represent N; R represents optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl, etc.; R1 to R4 represent H, a halogen atom, etc.) or pharmaceutically acceptable salts thereof, or prodrugs thereof, which exert an excellent inhibitory activity in human SGLT2 and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications, obesity or the like, pharmaceutical compositions comprising the same, and medicinal uses thereof.

摘要翻译： 本发明提供由以下通式表示的含氮杂环衍生物：其中X 1表示Nor CR 1; X <2>表示Nor CR 2; X 3表示N或CR 3; X 4表示N或CR 4; 并且条件是X 1至X 4中的一个或两个表示N; R表示任选取代的C 3-8环烷基，任选取代的C 6-10芳基等; R 1至R 4代表H，卤素原子等）或其药学上可接受的盐或其前药，其在人SGLT2中具有优异的抑制活性，并且为 可用作预防或治疗与高血糖相关的疾病如糖尿病，糖尿病并发症，肥胖症等的药剂，其药物组合物及其药物用途。

公开(公告)号：US20060025352A1

公开(公告)日：2006-02-02

申请号：US11247216

申请日：2005-10-12

申请人： Hideki Fujikura ,  Nobuhiko Fushimi ,  Toshihiro Nishimura ,  Takeshi Nakabayashi ,  Masayuki Isaji

发明人： Hideki Fujikura ,  Nobuhiko Fushimi ,  Toshihiro Nishimura ,  Takeshi Nakabayashi ,  Masayuki Isaji

IPC分类号： A61K31/7052 ,  C07H17/02

CPC分类号： A61K45/06 ,  A61K31/7056 ,  C07H17/02 ,  A61K2300/00

摘要： The present invention provides glucopyranosyloxypyrazole derivatives represented by the general formula: wherein R represents a hydrogen atom, a lower alkyl group or a group forming a prodrug;.one of Q and T represents a group represented by the general formula: (wherein P represents a hydrogen atom or a group forming a prodrug), while the other represents a lower alkyl group or a halo(lower alkyl) group; R2 represents a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a halo(lower alkyl) group or a halogen atom; and with the proviso that P does not represent a hydrogen atom when R represents a hydrogen atom or a lower alkyl group, or pharmaceutically acceptable salts thereof, which exert an inhibitory activity in human SGLT2 and have an improved oral absorption, and therefore are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications or obesity, and pharmaceutically acceptable salts thereof, and pharmaceutical uses thereof.

摘要翻译： 本发明提供由以下通式表示的吡喃葡萄糖氧吡唑衍生物：其中R表示氢原子，低级烷基或形成前药的基团; Q和T表示由以下通式表示的基团：（其中P表示 氢原子或形成前药的基团），而另一个表示低级烷基或卤代（低级烷基）基团; R 2表示氢原子，低级烷基，低级烷氧基，低级烷硫基，卤代（低级烷基）或卤素原子; 并且条件是当R表示氢原子或低级烷基时，P不表示氢原子，或其药学上可接受的盐，其在人SGLT2中具有抑制活性并具有改善的口服吸收，因此可用作 用于预防或治疗与高血糖相关的疾病如糖尿病，糖尿病并发症或肥胖症的药剂及其药学上可接受的盐及其药学用途。

公开(公告)号：US20050080022A1

公开(公告)日：2005-04-14

申请号：US10959505

申请日：2004-10-07

申请人： Hideki Fujikura ,  Nobuhiko Fushimi ,  Toshihiro Nishimura ,  Kazuya Tatani ,  Kenji Katsuno ,  Masahiro Hiratochi ,  Yoshiki Tokutake ,  Masayuki Isaji

发明人： Hideki Fujikura ,  Nobuhiko Fushimi ,  Toshihiro Nishimura ,  Kazuya Tatani ,  Kenji Katsuno ,  Masahiro Hiratochi ,  Yoshiki Tokutake ,  Masayuki Isaji

IPC分类号： A61K31/7034 ,  A61P3/04 ,  A61P3/10 ,  A61P43/00 ,  C07C39/04 ,  C07C69/16 ,  C07C69/18 ,  C07C69/78 ,  C07C323/18 ,  C07H15/203 ,  A61K31/704 ,  C07H15/04

CPC分类号： C07H15/203

摘要： The present invention relates to glucopyranosyloxybenzylbenzene derivatives represented by the general formula: wherein R1 represents a hydrogen atom or a hydroxy(lower alkyl) group; and R2 represents a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a hydroxy(lower alkyl) group, a hydroxy(lower alkoxy) group, a hydroxy(lower alkylthio) group etc., and salts thereof, which have an excellent inhibitory activity in human SGLT2 and are useful as agents for the prevention or treatment of diabetes, obesity etc., and intermediates thereof.

摘要翻译： 本发明涉及由以下通式表示的吡喃葡萄糖氧基苄基苯衍生物：其中R 1表示氢原子或羟基（低级烷基）; R 2表示低级烷基，低级烷氧基，低级烷硫基，羟基（低级烷基），羟基（低级烷氧基），羟基（低级烷硫基）等，及其盐 ，其在人SGLT2中具有优异的抑制活性，并且可用作预防或治疗糖尿病，肥胖症等及其中间体的药剂。

公开(公告)号：US20050075294A1

公开(公告)日：2005-04-07

申请号：US10959509

申请日：2004-10-07

申请人： Hideki Fujikura ,  Nobuhiko Fushimi ,  Toshihiro Nishimura ,  Kazuya Tatani ,  Kenji Katsuno ,  Masahiro Hiratochi ,  Yoshiki Tokutake ,  Masayuki Isaji

发明人： Hideki Fujikura ,  Nobuhiko Fushimi ,  Toshihiro Nishimura ,  Kazuya Tatani ,  Kenji Katsuno ,  Masahiro Hiratochi ,  Yoshiki Tokutake ,  Masayuki Isaji

IPC分类号： A61K31/7034 ,  A61P3/04 ,  A61P3/10 ,  A61P43/00 ,  C07C39/04 ,  C07C69/16 ,  C07C69/18 ,  C07C69/78 ,  C07C323/18 ,  C07H15/203 ,  A61K31/704 ,  C07H15/04

CPC分类号： C07H15/203

摘要： The present invention relates to glucopyranosyloxybenzylbenzene derivatives represented by the general formula: wherein R1 represents a hydrogen atom or a hydroxy(lower alkyl) group; and R2 represents a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a hydroxy(lower alkyl) group, a hydroxy(lower alkoxy) group, a hydroxy(lower alkylthio) group etc., and salts thereof, which have an excellent inhibitory activity in human SGLT2 and are useful as agents for the prevention or treatment of diabetes, obesity etc., and intermediates thereof.